

Freedom of Information Request: Our Reference CTMUHB_114_22

You asked:

Q1. In the past 6 months (latest 6 months available) how many patients have received the following Immunoglobulin treatments (for any disease):

- **Cutaquig**
- **Cuvitru**
- **Gammanorm**
- **Hizentra**
- **Hyqvia**
- **Subgam**
- **Privigen**
- **Octagam**
- **Intratect**
- **Gamunex**
- **Kiovig**
- **Panzyga**
- **Iqymune**
- **Gammaplex**

Please find below a table populated with the data that Medicines Management are able to provide in relation to Q1 and Q2. The period the data relates to is the latest 6 months available September 21 to February 22.

Medicine	Total Patients
Cutaquig	
Cuvitru	
Gammanorm	
Hizentra	
Hyqvia	**
Subgam	
Privigen	24
Octagam	**
Intratect	
Gamunex	15
Kiovig	
Panzyga	
Iqymune	**
Gammaplex	

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection

Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test

Q2. In the past 6 months (latest 6 months available) how many patients have received the following treatments (for any disease):

- **Berinert (Human C1-esterase inhibitor)**
- **Cinryze (Human C1-esterase inhibitor)**
- **Firazyr (Icatibant injection)**
- **Orladeyo (Berotralstat)**
- **Ruconest (Recombinant Human C1-esterase inhibitor)**
- **Takhzyro (Lanadelumab)**

Medicine	Total Patients
Berinert (Human C1-esterase inhibitor)	0
Cinryze (Human C1-esterase inhibitor)	0
Firazyr (Icatibant injection)	0
Orladeyo (Berotralstat)	0
Ruconest (Recombinant Human C1-esterase inhibitor)	0
Takhzyro (Lanadelumab)	0

Q3. In the past 2 years, how many patients have been diagnosed (primary and secondary) with Hereditary Angioedema (ICD-10 code D84.1).

We do not centrally record the diagnosis allocated to patients, this could occur in a GP, ambulatory care, ED setting, etc. The only mandated diagnosis centrally recorded by the Health Board is for patients admitted as an inpatient; we are therefore unable to provide the requested information.

Q4. For the patients identified in Q3 above, how many patients have been treated (for any condition) in the past 6 months with the following drugs:

- **Danazol**
- **Oxandralone**
- **Stanozolol**

Please see response to question 3. We can confirm that the Health Board does not centrally record this information. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.